COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Joint Proteomic and Genomic Data Release for Head and Neck Squamous Cell Carcinoma

108 cases of the NCI’s Clinical Proteomic Tumor Analysis Program (CPTAC) Head and Neck Squamous Cell Carcinoma Discovery Study have been proteomically and genomically profiled!  Each case includes HPV-negative, treatment naive and normal adjacent tissue, and includes proteomic ad phosphoproteomic data on the Proteomic Data Commons (PDC), as well as RNA-Seq, miRNA-Seq, WGS, WXS genomic data on the Genomic Data Commons (GDC).   

CPTAC HNSCC Discovery Study - Proteome - https://pdc.cancer.gov/pdc/study/PDC000221
CPTAC HNSCC Discovery Study - Phosphoproteome - https://pdc.cancer.gov/pdc/study/PDC000222

Head and neck squamous cell carcinoma is the seventh most common cancer worldwide, accounting for approximately 3% of all cancers worldwide.  In the United States it is estimated that in 2020 there will be 53,000 new cases and over 10,000 deaths (National Cancer Institute; NCI, Surveillance, Epidemiology, and End Results Program; SEERS).  These tumors are challenging to treat because of their genetic complexity and heterogeneous nature. 

The Office of Cancer Clinical Proteomics Research (OCCPR) aims to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advancing proteome/proteogenome science and technology development through community resources (data and reagents), and accelerating the translation of molecular findings into the clinic.